Description
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate for the treatment of adults with triple-negative breast cancer (TNBC) that has spread to other parts of the body and have received at least two prior therapies.
Sacituzumab govitecan has a boxed warning about the risk of severe neutropenia (abnormally low levels of white blood cells) and severe diarrhea.
Sacituzumab govitecan may cause harm to a developing fetus or newborn baby.